MAPT and Alzheimer disease: In this paper, we show that chronic administration of a pharmacological chaperone by upregulating VPS35 improves memory and synaptic integrity, lowers Aβ levels and deposition, decreases tau pathology and neuroinflammation in a transgenic mouse model of AD.